Advertisement

Patient Management in Clinical Practice

  • Timothy H. M. FungEmail author
  • Winfried M. K. Amoaku
Chapter
  • 21 Downloads

Abstract

This chapter provides an in-depth evidence-based approach and management of common corneal, retinal, oculoplastic, paediatric, neuro-ophthalmic and glaucomatous scenarios seen in clinical practice. Illustrations of pathologies are provided where relevant.

Keywords

History Examination Investigations Treatment Diagnoses 

References

  1. An International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123:991–9.Google Scholar
  2. Azuara-Blanco A, Burr J, Ramsay C, Cooper D, Foster PJ, Friedman DS, Scotland G, Javanbakht M, Cochrane C, Norrie J. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet. 2016;388:1389–97.PubMedGoogle Scholar
  3. Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, Wilhelmus KR, Kaufman HE, Sugar J, Hyndiuk RA, Laibson PR, Stulting RD, Asbell PA. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1871–82.PubMedGoogle Scholar
  4. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Concensus statement of the European group on graves orbitopathy (EUGOGO) on management of graves orbitopathy. Thyroid. 2008;18:333–46.PubMedGoogle Scholar
  5. Bhatnagar P, Kaiser PK, Smith SD, Meisler DM, Lewis H, Sears JE. Reopening of previously closed macular holes after cataract extraction. Am J Ophthalmol. 2007;144:252–9.PubMedGoogle Scholar
  6. Boyer DS, Heier MD, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion. Six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024–32.PubMedGoogle Scholar
  7. Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM. Three-year, randomised, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14.PubMedPubMedCentralGoogle Scholar
  8. British Society for Paediatric and Adolescent Rheumatology and the Royal College of Ophthalmologists. Guidelines for screening for uveitis in Juvenile Idiopathic Arthritis (JIA). [Online]. London: British Society for Paediatric and Adolescent Rheumatology, The Royal College of Ophthalmologists; 2006. https://www.rcophth.ac.uk/wp-content/uploads/2017/08/2006_PROF_046_JuvenileArthritis-updated-crest.pdf. Accessed 11 Dec 2019.Google Scholar
  9. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY. Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124–33.PubMedGoogle Scholar
  10. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patal S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins J. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22.PubMedGoogle Scholar
  11. Brown DM, Schmidt-Erfurth I, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122:2044–52.PubMedGoogle Scholar
  12. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120:1843–51.PubMedGoogle Scholar
  13. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG. Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102–12.PubMedGoogle Scholar
  14. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA. Intravitral aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538–44.PubMedGoogle Scholar
  15. Chandler JR, Langenbrunner DJ, Stevens ER. The pathogenesis of orbital complications in acute sinusitis. Laryngoscope. 1970;80:1414–28.PubMedGoogle Scholar
  16. Chung SE, Kim KH, Kang SW. Retinal breaks associated with the induction of posterior vitreous detachment. Am J Ophthalmol. 2009;147:1012–6.PubMedGoogle Scholar
  17. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.Google Scholar
  18. Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K. Sustained delivery fluocinolone acetonide vitreous implants. Long term benefits in patients with chronic diabetic macular oedema. Ophthalmology. 2014;121:1892–903.PubMedPubMedCentralGoogle Scholar
  19. Debette S, Leys D. Cervical artery dissections: predisposing factors, diagnosis, and outcome. Lancet Neurol. 2009;8:668–78.PubMedGoogle Scholar
  20. de Bustros S. Vitrectomy for prevention of macular holes. Results of a randomised multicenter clinical trial. Vitrectomy for Prevention of Macular Hole Study Group. Ophthalmology. 1994;101:1055–9.PubMedGoogle Scholar
  21. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology. 1995;102:647–61.Google Scholar
  22. Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120:2611–9.PubMedGoogle Scholar
  23. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991a;98:766–85.Google Scholar
  24. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991b;98:823–33.Google Scholar
  25. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomised trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479–96.Google Scholar
  26. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978–88.Google Scholar
  27. European Carotid Surgery Trialists Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0-29%) carotid stenosis. Lancet. 1991;337:1235–43.Google Scholar
  28. Ezra E, Wells JA, Gray RH, Kinsella FM, Orr GM, Grego J, Arden GB, Gregor ZJ. Incidence of idiopathic full-thickness macular holes in fellow eyes. A 5-year prospective natural history study. Ophthalmology. 1998;105:353–9.PubMedGoogle Scholar
  29. Ezra E. Idiopathic full thickness macular hole: natural history and pathogenesis. Br J Ophthalmol. 2001;85:102–8.PubMedPubMedCentralGoogle Scholar
  30. Ferguson GG, Eliasziw M, Barr HWK, Clagett P, Barnes RW, Wallace MC, Taylor DW, Haynes RB, Finan JW, Hachinski VC, Barnett HJM. The North American symptomatic carotid endarterectomy trial. Stroke. 1999;30:1751–8.PubMedGoogle Scholar
  31. Freeman WR, Azen SP, Kim JW, el-Haig W, Mishell DR III, Bailey I. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomised clinical trial. The Vitrectomy for Treatment of Macular Hole Study Group. Arch Ophthalmol. 1997;115:11–21.PubMedGoogle Scholar
  32. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81:1159–65.Google Scholar
  33. Garcia GH, Harris GJ. Criteria for nonsurgical management of subperiosteal abscess of the orbit: analysis of outcomes 1988-1998. Ophthalmology. 2000;107:1454–6.PubMedGoogle Scholar
  34. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S. A randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473–81.PubMedGoogle Scholar
  35. Guillaubey A, Malvitte L, Lafontaine PO, Hubert I, Bron A, Berrod JP, Creuzot-Garcher C. Incidence of retinal detachment after macular surgery. Br J Ophthalmol. 2007;91:1327–30.PubMedPubMedCentralGoogle Scholar
  36. Guzzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393:1505–16.Google Scholar
  37. Haggerty H, Richardson S, Hrisos S, Strong NP, Clarke MP. The Newcastle Control Score: a new method of grading the severity of intermittent distance exotropia. Br J Ophthalmol. 2004;88:233–5.PubMedPubMedCentralGoogle Scholar
  38. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillie M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM. Randomised, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–46.PubMedPubMedCentralGoogle Scholar
  39. He M, Jiang Y, Huang S, Chang DS, Munoz B, Aung T, Foster PJ, Friedman DS. Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial. Lancet. 2019;393:1609–18.PubMedGoogle Scholar
  40. Heijl A, Leske C, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression. Results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268–79.PubMedGoogle Scholar
  41. Herpetic Eye Disease Study Group. Psychological stress and other potential triggers for recurrences of herpes simplex virus eye infections. Arch Ophthalmol. 2000;118:1617–25.Google Scholar
  42. Herpetic Eye Disease Study Group. Predictors of recurrent herpes simplex virus keratitis. Cornea. 2001;20:123–8.Google Scholar
  43. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R. VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97:278–84.PubMedGoogle Scholar
  44. Infant Aphakia Treatment Study Group, Lambert SR, Buckley EG, Drews-Botsch C, DuBois L, Hartmann EE, Lynn MJ, Plager DA, Wilson ME. A randomised clinical trial comparing contact lens with intraocular lens correction of monocular aphakia during infancy: grating acuity and adverse events at age 1 year. Arch Ophthalmol. 2010;128:810–8.Google Scholar
  45. Infant Aphakia Treatment Study Group, Lambert SR, Lynn MJ, Hartmann EE, DuBois L, Drews-Botsch C, Freedman SF, Plager DA, Buckley EG, Wilson ME. Comparison of contact lens and intraocular lens correction of monocular aphakia during infancy: a randomised clinical trial of HOTV optotype acuity at age 4.5 years and clinical findings at age 5 years. JAMA Ophthalmol. 2014;132:676–82.Google Scholar
  46. Ip MS, Baker BJ, Duker JS, Reichel E, Baumal CR, Gangnon R, Puliafito CA. Anatomic outcomes of surgery for idiopathic macular hole as determined by optical coherence tomography. Arch Ophthalmol. 2002;120:29–35.PubMedGoogle Scholar
  47. Kamalarajah S, Silvestri G, Sharma N, Khan A, Foot B, Ling R, Cran G, Best R. Surveillance of endophthalmitis following cataract surgery in the UK. Eye (London). 2004;18:580–7.Google Scholar
  48. Kelly SP, Mathews D, Mathews J, Vail A. Reflective consideration of postoperative endophthalmitis as a quality marker. Eye (London). 2007;21:1419–26.Google Scholar
  49. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520–6.PubMedGoogle Scholar
  50. Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, Guiband L, Baselga E, Posiunas G, Phillips RK, Caceres H, Gutierrez JCL, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Pray S, Boralevi F, Morgan CC, Heritier S, Delarue A, Voisard JJ. A randomised, controlled trial of oral propranolol in infantile haemangioma. N Engl J Med. 2015;372:735–46.PubMedGoogle Scholar
  51. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomised to medications or surgery. Ophthalmology. 2001;108:1943–53.PubMedPubMedCentralGoogle Scholar
  52. Lincoff H, Gieser R. Finding the retinal hole. Arch Ophthalmol. 1971;85:565–9.PubMedGoogle Scholar
  53. MacEwan CJ, Young JD. The fluorescein disappearance test (FDT): an evaluation of its use in infants. J Pediatr Ophthalmol Strabismus. 1991;28:302–5.Google Scholar
  54. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds C, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, O’Sullivan E, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford). 2020;59:487–494. pii: kez664.  https://doi.org/10.1093/rheumatology/kez664. [Epub ahead of print].
  55. McCannel CA, Ensminger JL, Diehl NN, Hodge DN. Population-based incidence of macular holes. Ophthalmology. 2009;116:1366–9.PubMedPubMedCentralGoogle Scholar
  56. Markus HS, Levi C, King A, Madigan K, Norris J. Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: the cervical artery dissection in stroke study (CADISS) randomized clinical trial final results. JAMA Neurol. 2019;76:657–64.PubMedPubMedCentralGoogle Scholar
  57. McDonnell PJ, Fine SL, Hillis AI. Clinical features of idiopathic macular cysts and holes. Am J Ophthalmol. 1982;93:777–86.PubMedGoogle Scholar
  58. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A. The RESTORE study. Ranibuzumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.PubMedGoogle Scholar
  59. Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, Krishnan A, Chavda SV, Ramalingam S, Edwards J, Hemmings K, Williamson M, Burdon MA, Hassan-Smith G, Digre K, Liu GT, Jensen RH, Sinclair AJ. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89:1088–100.PubMedPubMedCentralGoogle Scholar
  60. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with graves ophthalmopathy. Clin Endocrinol (Oxford). 1997;47:9–14.Google Scholar
  61. National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion [TA229]. [Online]. London: NICE; 2011. https://www.nice.org.uk/guidance/ta229. Accessed 11 Dec 2019.Google Scholar
  62. National Institute for Health and Care Excellence. Ranibizumab for treating diabetic macular oedema [TA274]. [Online]. London: NICE; 2013a. https://www.nice.org.uk/guidance/ta274. Accessed 11 Dec 2019.Google Scholar
  63. National Institute for Health and Care Excellence. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion [TA283]. [Online]. London: NICE; 2013b. https://www.nice.org.uk/guidance/ta283. Accessed 11 Dec 2019.Google Scholar
  64. National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy [TA301]. [Online]. London: NICE; 2013c. https://www.nice.org.uk/guidance/ta301. Accessed 11 Dec 2019.Google Scholar
  65. National Institute for Health and Care Excellence. Ocriplasmin for treating vitreomacular traction [TA297]. [Online]. London: NICE; 2013d. https://www.nice.org.uk/guidance/ta297. Accessed 11 Dec 2019.Google Scholar
  66. National Institute for Health and Care Excellence. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion [TA305]. [Online]. London: NICE; 2014. https://www.nice.org.uk/guidance/ta305. Accessed 11 Dec 2019.Google Scholar
  67. National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema [TA346]. [Online]. London: NICE; 2015a. https://www.nice.org.uk/guidance/ta346. Accessed 11 Dec 2019.Google Scholar
  68. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period [NG3]. [Online]. London: NICE; 2015b. https://www.nice.org.uk/guidance/ng3. Accessed 11 Dec 2019.Google Scholar
  69. National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for treating diabetic macular oedema [TA349]. [Online]. London: NICE; 2015c. https://www.nice.org.uk/guidance/ta349. Accessed 11 Dec 2019.Google Scholar
  70. National Institute for Health and Care Excellence. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion [TA409]. [Online]. London: NICE; 2016. https://www.nice.org.uk/guidance/ta409. Accessed 11 Dec 2019.Google Scholar
  71. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management [NG81]. [Online]. London: NICE; 2017a. https://www.nice.org.uk/guidance/ng81. Accessed 11 Dec 2019.Google Scholar
  72. National Institute for Health and Care Excellence. Cataracts in adults: management [NG77]. [Online]. London: NICE; 2017b. https://www.nice.org.uk/guidance/ng77. Accessed 30 Nov 2019.Google Scholar
  73. National Institute for Health and Care Excellence. Tocilizumab for treating giant cell arteritis [TA518]. [Online]. London: NICE; 2018. https://www.nice.org.uk/guidance/ta518. Accessed 11 Dec 2019.Google Scholar
  74. National Institute for Health and Care Excellence. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management [NG128]. [Online]. London: NICE; 2019. https://www.nice.org.uk/guidance/ng128. Accessed 11 Dec 2019.Google Scholar
  75. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins J, Rubio RG, Ehrlich JS. Ranibizumab for diabetic macular edema. Results from 2 phase III randomised trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.PubMedGoogle Scholar
  76. The Pediatric Eye Disease Investigator Group. Randomised trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005;123:437–47.Google Scholar
  77. Prajna NV, Krishnan T, Mascarenhas MD, Rajaraman R, Prajna L, Srinivasan M, Raghavan A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Porco TC, Acharya NR. The mycotic ulcer treatment trial. A randomised trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013;131:422–9.PubMedPubMedCentralGoogle Scholar
  78. Public Health England. NHS Diabetic Eye Screening Programme. Grading definitions for referable disease. Public Health England leads the NHS Screening Programmes. [Online]. London: Public Health England; 2017. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/582710/Grading_definitions_for_referrable_disease_2017_new_110117.pdf . Accessed 11 Dec 2019.Google Scholar
  79. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545–54.Google Scholar
  80. Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists, British Association of Perinatal Medicine & Bliss. UK Retinopathy of Prematurity Guideline. [Online]. London: Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists, British Association of Perinatal Medicine & Bliss; 2008. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2008-SCI-021-Guidelines-Retinopathy-of-Prematurity.pdf. Accessed 11 Dec 2019.Google Scholar
  81. Ruby AJ, Williams DF, Grand MG, Thomas MA, Meredith TA, Boniuk I, Olk RJ. Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol. 1994;112:359–64.PubMedGoogle Scholar
  82. Saidkasimova S, Mitry D, Singh J, Yorston D, Charteris DG. Retinal detachment in Scotland is associated with affluence. Br J Ophthalmol. 2009;93:1591–4.PubMedGoogle Scholar
  83. Sharma MC, Regillo CD, Shuler MF, Borrillo JL, Benson WE. Determination of the incidence and clinical characteristics of subsequent retinal tears following treatment of the acute posterior vitreous detachment-related initial retinal tears. Am J Ophthalmol. 2004;138:280–4.PubMedGoogle Scholar
  84. Smiddy WE, Michels RG, Glaser BM, de Bustros S. Vitrectomy for impending idiopathic macular holes. Am J Ophthalmol. 1988;105:371–6.PubMedGoogle Scholar
  85. Solebo AL, Lange CAK, Bunce C, Bainbridge JW. Face-down positioning or posturing after macular hole surgery. Cochrane Database Syst Rev. 2011;(12):CD008228.  https://doi.org/10.1002/14651858.CD008228.pub2.
  86. Solebo AL, Cumberland P, Rahi JS. 5-year outcomes after primary intraocular lens implantation in children aged 2 years or younger with congenital or infantile cataract: findings from the IoLunder2 prospective inception cohort study. Lancet Child Adolesc Health. 2018;2:863–71.PubMedGoogle Scholar
  87. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, Mcleod SD, Lietman TM, Acharya NR. Corticosteroids for bacterial keratitis. The steroids for corneal ulcers trial (SCUT). Arch Ophthalmol. 2012;130:143–50.PubMedGoogle Scholar
  88. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, O’Brien KS, Glidden DV, Ray KJ, Oldenburg CE, Zegans ME, Whitcher JP, Mcleod SD, Porco TC, Lietman TM, Acharya NR. The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomised controlled trial. Am J Ophthalmol. 2014;157:327–33.PubMedGoogle Scholar
  89. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–28.PubMedGoogle Scholar
  90. Tanner V, Williamson TH. Watzke-Allen slit beam test in macular holes confirmed by optical coherence tomography. Arch Ophthalmol. 2000;118:1059–63.PubMedGoogle Scholar
  91. The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.Google Scholar
  92. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 4. Comparison of treatment outcomes within race. Ophthalmology. 1998;105:1146–64.Google Scholar
  93. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol. 2001;132:311–20.Google Scholar
  94. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271–82.Google Scholar
  95. The Branch Vein Occlusion Study Group. Prevention of neovascularisation and vitreous hemorrhage in branch vein occlusion. Arch Ophthalmol. 1986;104:34–41.Google Scholar
  96. The CADISS Trial Investigators. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015;14:361–7.Google Scholar
  97. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486–91.Google Scholar
  98. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomised trial — diabetic retinopathy vitrectomy study report 3. Ophthalmology. 1988;95:1307–20.Google Scholar
  99. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88:583–600.Google Scholar
  100. The Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. Arch Ophthalmol. 1996;114:1065–72.Google Scholar
  101. The Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339:300–6.Google Scholar
  102. The Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol. 2002;120:268–78.Google Scholar
  103. The Pediatric Eye Disease Investigator Group. A randomised trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol. 2003a;121:603–11.Google Scholar
  104. The Pediatric Eye Disease Investigator Group. A randomised trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology. 2003b;110:2075–87.Google Scholar
  105. The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines. [Online]. London: The Royal College of Ophthalmologists; 2012. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-301-FINAL-DR-GUIDELINES-DEC-2012-updated-July-2013.pdf. Accessed 11 Dec 2019.Google Scholar
  106. The Royal College of Ophthalmologists. Retinal Vein Occlusion (RVO) Guidelines. [Online]. London: The Royal College of Ophthalmologists; 2015. https://www.rcophth.ac.uk/wp-content/uploads/2015/07/Retinal-Vein-Occlusion-RVO-Guidelines-July-2015.pdf. Accessed 11 Dec 2019.Google Scholar
  107. The Royal College of Ophthalmologists. Ophthalmic Services Guidance for the Management of acute retinal detachment. [Online]. London: The Royal College of Ophthalmologists; 2010. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010_PROF_064_OSG-Retinal-Detachment-June-2010.pdf. Accessed 11 Dec 2019.Google Scholar
  108. The Royal College of Ophthalmologists. Ophthalmic Services Guidance for Managing an outbreak of postoperative endophthalmitis. [Online]. London: The Royal College of Ophthalmologists; 2016. https://www.rcophth.ac.uk/wp-content/uploads/2016/07/Managing-an-outbreak-of-postoperative-endophthalmitis.pdf. Accessed 11 Dec 2019.Google Scholar
  109. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.Google Scholar
  110. Wilhelmus KR, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, Barron BA, Kaufman HE, Sugar J, Hyndiuk RA, Laibson PR, Stulting RD, Asbell PA. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1883–96.PubMedGoogle Scholar
  111. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.Google Scholar
  112. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, Davis MD, Feman SS, Ferris F, Friedman SM, Garcia CA, Glassman AR, Han DP, Le D, Kollman C, Lauer AK, Recchia FM, Solomon SD. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125:469–80.Google Scholar
  113. Yamashita T, Uemara A, Uchino E, Doi N, Ohba N. Spontaneous closure of traumatic macular hole. Am J Ophthalmol. 2002;133:230–5.PubMedGoogle Scholar

Copyright information

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Timothy H. M. Fung
    • 1
    • 2
    Email author
  • Winfried M. K. Amoaku
    • 1
    • 3
  1. 1.Nottingham University Hospitals NHS Trust, Queen’s Medical CentreNottinghamUK
  2. 2.Royal Derby HospitalDerbyUK
  3. 3.University of NottinghamNottinghamUK

Personalised recommendations